BCI
SCPH

Brinker Capital Investments’s scPharmaceuticals SCPH Stock Holding History

Brinker Capital Investments’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-112
Closed – – 915
2019
Q2 		$0 Buy
+112
New +$366 ﹤0.01% 960

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
AIM
Alambic Investment Management Belvedere, California $9.12M AUM 34.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brinker Capital Investments's SCPH Position: Q3 2019 in Review

Brinker Capital Investments sold out of scPharmaceuticals (SCPH) in Q3 2019, closing a stake of 112 shares.

Brinker Capital Investments first reported a position in SCPH in Q2 2019 and held it in 1 quarter. The position peaked at $0 in Q2 2019. 26 funds tracked by Wall St. Rank hold SCPH as of Q3 2019.

  • Brinker Capital Investments reported no remaining scPharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Brinker Capital Investments sold 112 scPharmaceuticals shares in Q3 2019.
  • Brinker Capital Investments first reported a position in scPharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Brinker Capital Investments's scPharmaceuticals position peaked at $0 in Q2 2019.
  • 26 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2019.

Based on Brinker Capital Investments's 13F filing for Q3 2019, filed 14 Nov 2019.